A Montana resident is seeking experimental medical options for his three-year-old son, Brody, who was diagnosed with creatine transporter deficiency (CTD). The rare genetic disorder prevents the brain from utilizing creatine for essential energy, leading to significant developmental delays, muscle weakness, and a total inability to communicate. Because no approved treatment currently exists for this condition, families are looking toward emerging biotech solutions that have yet to complete standard clinical regulatory pathways.

According to MIT Technology Review, the French firm Ceres Brain Therapeutics is developing a potential nasal spray treatment designed to bypass the metabolic limitations of CTD. While the treatment has demonstrated positive outcomes in animal models and recently concluded a Phase I safety trial in 48 healthy adult volunteers, it remains unavailable for pediatric clinical use. The experimental nature of such drugs typically excludes them from standard medical care until full regulatory approval is secured, creating a desperate search for alternatives.

Montana’s new “right to try” legislation is intended to bridge this gap by theoretically enabling patients with life-threatening conditions to access investigative drugs that have passed initial safety testing but lack full market authorization. For parents like the DeVaults, this legal shift represents a critical, albeit uncertain, opportunity to pursue treatment for children whose neurological development remains time-sensitive. The effectiveness of this state-level policy in facilitating actual access to these specialized biotech products remains to be seen as the industry navigates the complexities of rare disease research.